An open-label, randomized, phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFr) antibody, versus best supportive care, in patients with noncurable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based chemotherapy (ZALUTE).

J. H. Machiels, Paul M. Clément, Ágnes Ruzsa et al.|Journal of Clinical Oncology|2010

Cited by 13